BG Reports 257 Percent Jump in Q3 Revenues, May Offer CardioScore Through CLIA Lab as LDT
November 16, 2012
BG Reports 257 Percent Jump in Q3 Revenues, May Offer CardioScore Through CLIA Lab as LDT
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- BG Medicine Revenues Jump to $622K in Q2; Firm Withdraws CardioScore 510(k)
August 10, 2012 / ProteoMonitor - BG Medicine Posts 85 Percent Jump in Q1 Revenues, Appoints New CEO
May 10, 2013 / ProteoMonitor - With $10M in Funding and New Distribution Pact, Aviir Rolls out Protein Test for Cardiac Risk
March 1, 2013 / ProteoMonitor - CMS Declines to Offer Higher Payment Rate for BG Medicine's Galetin-3 Test Under New CPT Code
November 9, 2012 / ProteoMonitor - BG Medicine Q2 Revenues Spike; Company Withdraws FDA Submission for CardioScore Test
August 9, 2012 / GenomeWeb Daily News